HomeABBV • NYSE
add
AbbVie Inc
Previous close
$185.42
Day range
$185.79 - $188.99
Year range
$163.52 - $218.66
Market cap
329.95B USD
Avg Volume
5.78M
P/E ratio
79.65
Dividend yield
3.51%
Primary exchange
NYSE
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Mar 2025info | Y/Y change |
---|---|---|
Revenue | 13.34B | 8.39% |
Operating expense | 5.28B | 8.44% |
Net income | 1.29B | -6.06% |
Net profit margin | 9.64 | -13.31% |
Earnings per share | 2.46 | 6.49% |
EBITDA | 6.10B | 11.89% |
Effective tax rate | 22.40% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Mar 2025info | Y/Y change |
---|---|---|
Cash and short-term investments | 5.18B | -71.35% |
Total assets | 136.16B | -8.54% |
Total liabilities | 134.70B | -4.35% |
Total equity | 1.46B | — |
Shares outstanding | 1.77B | — |
Price to book | 231.77 | — |
Return on assets | 7.48% | — |
Return on capital | 14.21% | — |
Cash Flow
Net change in cash
(USD) | Mar 2025info | Y/Y change |
---|---|---|
Net income | 1.29B | -6.06% |
Cash from operations | 1.64B | -59.53% |
Cash from investing | -735.00M | 92.33% |
Cash from financing | -1.26B | -111.63% |
Net change in cash | -349.00M | -106.64% |
Free cash flow | 1.12B | -73.12% |
About
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. Its major products are: Humira, approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis and administered via injection; Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases; Rinvoq, used to treat arthritis; and Botox. Its other major products include Imbruvica to treat cancer, Vraylar to treat schizophrenia and bipolar disorder, Venclexta to treat leukemia and lymphoma, Mavyret to treat Hepatitis C, and Epkinly, a blood-cancer therapy developed in partnership with Genmab. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev and tavapadon.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. Wikipedia
Founded
Apr 10, 2012
Headquarters
Website
Employees
55,000